Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Absolute Antibody and University of Zurich Collaborate to Offer Synthetic Nanobodies Against SARS-CoV-2 Receptor Binding Domain

News Image

Combined with Absolute Antibody’s unique antibody engineering approach, we can harness even more potential from the nanobodies and help scientists worldwide fight against the COVID-19 pandemic.

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19. Under the partnership, the original nanobodies and newly engineered formats are now available to the global research community for use as serological controls and in COVID-19 therapeutic development. The synthetic nanobodies possess particular promise for the development of inhalable drugs, which could offer a convenient treatment option for the COVID-19 pandemic.

Nanobodies are small antibody fragments that can reach previously inaccessible parts of the body due to their compact size. Researchers are exploring their potential as inhalable COVID-19 drugs, which would be easier to administer and reach patient’s lungs faster than other treatment formulations. The laboratory of Markus Seeger at University of Zurich developed a rapid in vitro selection platform to generate synthetic nanobodies, known as sybodies, against the receptor binding domain (RBD) of SARS-CoV-2. Within a two-week timeframe, the lab had identified more than 60 unique anti-RBD sybodies from combinatorial display libraries.

Further research showed that six of the sybodies bound SARS-CoV-2 spike protein with very high affinity, while five of those also inhibited ACE2, the host cell receptor to which SARS-CoV-2 binds to initiate the COVID-19 infection. Moreover, two of the sybodies can simultaneously bind the RBD, which could enable the construction of a polyvalent antiviral drug. The SARS-CoV-2 sybodies are therefore valuable tools for coronavirus research, diagnostics and therapeutic development, and the panel is now available to researchers worldwide via Absolute Antibody’s online catalog.

Absolute Antibody recombinantly produces the SARS-CoV-2 synthetic nanobodies for ensured batch-to-batch reproducibility, high purity and low endotoxin levels. In addition, Absolute Antibody has used antibody engineering to fuse the nanobodies to Fc domains in different species, isotypes and subtypes. For example, the anti-RBD binders are now available with human IgG1, IgG3, IgM and IgA domains for use as serological controls. These recombinant engineered antibodies extend the applications of the sybodies by varying effector function and permitting increased half-life in in vivo studies.

“We are excited to partner with the Seeger lab to make their novel synthetic nanobodies more widely available to the research community,” said Dr. Michael Fiebig, Vice President Product Portfolio & Innovation at Absolute Antibody. “Combined with Absolute Antibody’s unique antibody engineering approach, we can harness even more potential from the nanobodies and help scientists worldwide fight against the COVID-19 pandemic.”

“The global research community has been working at unprecedented speeds to fight COVID-19,” said Dr. Markus Seeger, Professor at the Institute of Medical Microbiology of the University of Zurich. “By partnering with Absolute Antibody, we have extended the reach and applications of our new synthetic nanobodies, furthering their potential in the race to develop urgently required therapeutics.”

In addition to the new synthetic antibodies, Absolute Antibody offers a variety of other engineered reagents for coronavirus research, including SARS-CoV-2 spike glycoprotein and nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests. Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, such as the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.

For more information, and a full list of available synthetic nanobodies and engineered antibodies, please visit our website here.

About Absolute Antibody, Ltd.

Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Learn more here.

About University of Zurich

The University of Zurich (UZH) is a member of the League of European Research Universities and numbers among Europe’s most prestigious research institutions. UZH’s international standing is reflected in the many renowned academic distinctions conferred upon its members, including twelve Nobel Prizes. As Switzerland’s largest university, UZH has a current enrollment of over 26,000 students and offers the most comprehensive academic program in the country. Over 5,000 excellent members of staff teach and perform research at one of the University’s 150 departments, including over 675 professors. UZH also looks back on a rich history, having been founded in 1833 as Europe’s first university to be established by a democratic political System. The research group of Markus Seeger is located at the Institute of Medical Microbiology. For more information please visit and


Lisa Merolla    

Director of Marketing

+1 617-377-4057 (extension 610)


Share article on social media or email:

R3 International Offering New Program for Stem Cell Therapy for Alzheimers Dementia in Mexico

Stem Cell Therapy for Alzheimers

Stem Cell Therapy for Alzheimers at R3 International (888) 988-0515

Stem cell treatment for Alzheimers disease is showing amazing effectiveness in Mexico at R3 International, with up to 200 million stem cells being offered!

R3 International is now offering stem cell therapy for Alzheimers dementia in Mexico with a new program featuring up to 200 million stem cells. Depending on the patient’s condition, treatment may be offered IV, intrathecal or with a combination.

A third of seniors in the US will die having some form of Alzheimers dementia, and the incidence continues to increase as individuals live longer. There is no cure, and conventional treatments often do not help dramatically.

Enter stem cell therapy for Alzheimers in Mexico at R3 International. Several early studies have showed significant benefit for Alzheimers disease with stem cell treatment (Curr Opin Psychiatry, 2019).

Stem cells have the potential of altering regeneration of neurons and synapses. Anecdotally, R3 Stem Cell International has seen amazing response with patients suffering from Alzheimers dementia with regards to memory, conversational ability and ability to perform activities of daily living.

There are several treatment options in Tijuana with R3 International. Patients may receive a one time treatment with 30 million stem cells for only $2975, or receive 50 million stem cells for $1000 more.

The newest program at R3 International involves either a 5 day visit for several treatments, or four visits over a year. Treatment involves up to 200 million stem cells for these treatment options, which is an excellent amount for the Alzheimers treatment. These options start at only $8975.

Along with effective stem cell treatment options for Alzheimers, R3 International also offers effective stem cell therapy for stroke, neuropathy, ALS, MS, diabetes, liver/kidney failure, COPD, arthritis, Lupus, Lyme, psoriasis, RA and more.

The process starts with a free phone consultation with one of R3’s licensed, experience stem cell doctors. Once treatment is then scheduled, the patient concierge representative will assist with travel logistics. Transportation is offered between San Diego and the clinic, which is only 20 minutes from the SA airport.

To discuss stem cell treatment in Mexico options with R3, call (888) 988-0515.

Share article on social media or email:

Biocompare Announces the Launch of COVID-19 Focused Content Hub

Biocompare Launches COVID-19 Focused Content Hub

Biocompare Launches COVID-19 Focused Content Hub

Showcasing novel tools & technologies, scientific findings, and diagnostic and therapeutic advances related to the COVID-19 pandemic is consistent with our mission to educate scientists in the latest technology while providing tool providers with a unique way to engage with our audience.

The latest SARS-CoV-2 news, enabling technologies, and promising scientific breakthroughs are prominently featured in Biocompare’s latest content hub—Future Lab: COVID-19 R&D.

Future Lab is an interactive information resource designed to showcase the latest advancements, trends, news, and products within specific scientific niches. Since their launch four years ago, the Future Lab content hubs have become indispensable resources to life scientists around the world. The hubs are updated weekly, and regular alerts drive engagement with registered users.

The COVID-19 R&D Future Lab puts all of Biocompare’s Coronavirus-related content directly at users’ fingertips. The easy-to-navigate microsite breaks the content down by Research, Diagnostics, and Therapeutics, and includes overview articles, explanatory infographics, must-see guides, and expert tips. Educational information from the seven sponsoring companies—Acro Biosystems, Candor, Mabtech, PerkinElmer, Precision for Medicine, Sartorius, and Sino Biological—is also included.

Previous Future Labs have focused on other fundamental topics in life science research including Optimizing Workflows in the Life Sciences, Automated Sample Prep, Antibody Therapeutics, Genetic Analysis, Live Cell Imaging, Protein Production, Immunodetection, Cell Culture, Liquid Handling, Next Generation Sequencing, Flow Cytometry, and Biopharmaceutical Analysis.

“Being able to expand our Future Lab offerings to include the latest enabling tools and technologies, scientific findings, knowledge, and diagnostic and therapeutic developments related to the COVID-19 pandemic has been immensely satisfying for our team as well as consistent with our mission to educate scientists in the latest technology while providing the tool provider community a unique and novel way to engage with our audience. We are grateful to the sponsors who helped make this content hub an indispensable resource for the more than 3.3 million scientists who visit Biocompare every year.”

About Biocompare

Biocompare, a Division of CompareNetworks, Inc., is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative resource that enables them to make better product, technology, and service purchasing decisions. Produced by scientists, Biocompare’s mission is to provide free, time-saving services to life science researchers, allowing scientists to find and learn about the technologies that drive discovery. Biocompare continually strives to serve the life science community by providing new and improved online services that facilitate product discovery and technology education. For more information, please visit

Share article on social media or email:

Xtalks Announces Its Life Science Webinar Calendar for July 2020

Xtalks Life Science Webinars

Stay on top of current hot topics through free webinars presented by leading experts in pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Visit to see our upcoming webinars:


July 2- Optimizing Clinical Trials Using Adaptive Design: Early Alignment for Success

July 6- Bringing Clarity and Focus to Research Questions: ICH E9 (R1) Estimands and Sensitivity Analyses in Clinical Trials

July 7- Clinical Endpoints and Treatment Effect in Immuno-Oncology

July 9- Achieving High Performance Study Start-up: An Inside Look at GSK

July 13- The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like

July 14- Adapting Oncology Clinical Research Practices and Therapeutic Development Strategies in the Global COVID-19 Era

July 14- How Multispectral Imaging Enables Analysis of Macrophages in Chronic Liver Disease

July 14- Demystifying Decentralized Clinical Trials and Enabling Your Study for Success

July 16- Strategic Considerations for Successful Biosimilars Development

July 16- iRECIST Criteria: An Operational Approach in Oncology Clinical Trials

July 17- Protein Therapeutic Bioanalysis by Hybrid IA-LC-MS/MS: Optimization of a Preclinical Antibody Workflow

July 20- Accelerate Biomarker Discovery: Learn How to Mine Data for Actionable Insights

July 21- Ready or Not, COVID-19 Necessitates the Move to Decentralized Clinical Trials

July 21- Anatomy of a Successful Study Transition: If I Knew Then What I Know Now

July 23- The Evolving Role and Accelerated Adoption of Data Management Technology Strategies and Solutions

July 28- How Alcon Enabled Data Managers to Build Studies Directly from the Protocol

July 29- Phase I Studies in Patient Populations: De-risking Clinical Development by Obtaining Key Patient Data Earlier

July 29- Diabetes and CKD: The Patient Experience, Clinical Research and the Promise of Precision Medicine

July 30- Integrating Qualitative Patient Interviews into a Clinical Trial Protocol


July 7- Cost-Efficient and Green Manufacturing of Peptides Thanks to Molecular Hiving Technology

July 8- CRISPR Generated Models: A Framework for Reducing Risk and Timelines Through Careful Design and Planning for Downstream Services

July 10- LBA and Hybrid LCMS Quantitation of Biotherapeutics and Biomarkers

July 13- Biomarkers in Immuno-Oncology: Identifying and Implementing Biomarker Testing from Exploratory Research to Clinical Trials

July 15- The Role of the Laboratory Animal Diet in Shaping the Gut Microbiota

July 22- Remote Administration Considerations for Conventional and Computerized Clinical Outcome Assessments

July 23- Database Mapping: A Tool to Identify Real World Data Sources


July 15- Re-discover the More Planet-Friendly Way of Packaging: PAPER

July 22- Delivering Sustainable Business Benefits and ROI with FoodTech


July 8- Successfully Navigating Cost Barriers to Deliver Low Cost Connectivity to the Pharmaceutical Industry

July 9- The Future of Medical Devices: How COVID-19 and the Rise of Digital Health has changed Regulatory, Clinical, and Reimbursement Dynamics in the Medical Device Industry

July 13 – Drive Manufacturing Resilience Through the Virtual Twin Experience In Life Sciences


July 7- Optimize your Supply Chain with End-to-End Visibility

July 15- How to Comply with the New Revision of USP 1058 under a Lockdown

July 20- Implementing Precision Medicine: Diagnostics Policy Considerations for Biopharmaceutical Innovators

July 20- Applying AI and Cloud Technologies for Multivariate Control in Upstream Processes

July 22- COVID-19: Navigating the New Normal in Pharmaceutical Commercialization


Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

Share article on social media or email:

Lumeda Announces Formation of its Scientific Advisory Board

News Image

Lumeda Inc. (“Lumeda”), a biophotonics systems company advancing photodynamic therapy (PDT) for treating cancer, today announced the formation of its Scientific Advisory Board with the appointment of a panel of medical and scientific experts who will provide critical medical, scientific, and strategic advice to support company development and introduction of its PDT products to the clinic. The three charter members appointed are:

Dr. Justin D. Blasberg MD, MPH, FACS, Associate Professor of Surgery and Director of Robotic Thoracic Surgery at Yale School of Medicine. As a skilled surgeon, Dr. Blasberg performs the majority of his surgeries in a minimally invasive fashion. He leads a clinical research program on novel imaging techniques for the detection of lung cancer and surgical outcomes research in thoracic surgery.

Dr. Michael M. Conway MD, is a medical executive and Pulmonary Disease and Internal Medicine specialist practicing in Hartford, CT and affiliated with Hartford Hospital. A recognized pulmonary expert with strong regional ties, Dr. Conway brings to Lumeda significant knowledge and expertise in diagnosing and staging of respiratory cancers, and associated standards of care and treatment options.

Dr. Gal Shafirstein DSc, Professor of Oncology and Director of PDT Clinical Research at Roswell Park Comprehensive Cancer Center. Dr. Shafirstein leads PDT translational and clinical research at Roswell Park focused on treatment planning and light dosimetry for interstitial and intraoperative PDT. He is the principal investigator and inventor on the intraoperative PDT innovation for treating lung cancer that Lumeda is commercializing.

“We are very pleased to have such accomplished medical and scientific professionals augment our team to advance this important lung cancer therapy,” according to Paul Sanders, one of the founders of Lumeda. “This advisory group brings a broad range of expertise that is critical to Lumeda’s product design and longer term strategy”.

This panel of medical and PDT science experts was carefully chosen and augments the company photonics engineering and development capabilities to advance its PDT product design for treatment effectiveness and fitness for use in the operating room environment.

About Lumeda:

Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use, and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with significant expertise and strength in systems engineering, factory operations, and the commercialization of new products and technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit

Share article on social media or email:

Medisend College Welcomes Joyce Williams to the Board of Trustees

Joyce Williams

“Ms. Williams brings with her a wealth of experience and leadership to our Board. Her energy and passion for our mission will be an immeasurable asset to the organization and the students we serve. We proudly welcome her onboard,” General Richard B. Myers, USAF (ret)

Medisend College of Biomedical Engineering Technology, a Dallas-based nonprofit college whose mission is to provide high-quality, intensive education and training that prepares graduates for professional careers as field service engineers and biomedical equipment technicians, proudly announces Joyce Williams as new member of the Board of Trustees.

Ms. Williams currently serves as Associate Vice Chancellor of Workforce and Community Initiatives for the Dallas County Community College District (DCCCD), one of the largest undergraduate institutions of higher education in Texas. She is responsible for initiatives involving workforce development, community development, and business strategies. Her 20 plus years of experience in education includes several senior leadership positions at the post-secondary level.

The Medisend College Board of Trustees is chaired by General Richard B. Myers, USAF (ret), founder of the General Richard B. Myers Veterans Program at Medisend College, past Chairman of the Joint Chiefs of Staff and currently President of Kansas State University.

“Ms. Williams brings with her a wealth of experience and leadership to our Board. Her energy and passion for our mission will be an immeasurable asset to the organization and the students we serve. We proudly welcome her onboard,” says General Myers.

Ms. Williams was recognized in 2014 as one of the Top 25 Women of Dallas by the Steele Society. In addition, she holds the honor of being awarded by the Dallas Business Journal as one of the Minority Business Leaders for 2015 and 2016 Boys and Girls Club Outstanding Child Advocate Award. She has been recognized by the Dallas Business Journal as one of the 30 top Women in Business for Dallas in 2018. Ms. Williams was also recognized by Walker’s Legacy as one of the organization’s “Power 15” 2018 award recipients for career success in Dallas. She received Governor Greg Abbott recognition in 2018 for apprenticeship programs and was also awarded the 2020 Social Services award by the Interdenominational Ministerial Alliance (IMA). Most recently she led the development of a strategic implementation of the Amazon Veteran Apprenticeship program (Cloud Support Technician); development and management of 9-12 apprenticeship programs serving over 2000 apprentices.

Ms. Williams is actively involved in the community. Her current activities include: Past Chair, Boys and Girls Club of Greater Dallas; Executive Board member, Dallas Black Chamber of Commerce; Chair, Visit Dallas; Board member, Friends of Fair Park; member of the Texas Higher Education Coordinating Board (THECB) Certification Advisory Council; Appointed by the Texas Workforce Commissioner to the Apprenticeship Training and Advisory Committee (ATAC); Chair of the THECB WECM Advisory Committee and a Lifetime member of the NAACP.

“I have long supported Medisend College and am proud to join in an official capacity as a new member of the Board of Trustees. I look forward to being part of Medisend College’s excellence, particularly in support of our US veterans,” says Ms. Williams adding, “I am hopeful that my educational experience will be a welcome addition.”

For more information on Medisend College, go to

Share article on social media or email:

Imaging system from Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic research

High-resolution, multi-channel COVID-19 cellular images captured using the ImageXpress Micro Confocal system from Molecular Devices

We commend Recursion for empowering researchers with the statistically relevant data to advance our understanding of COVID-19 cellular responses and drug discovery. This is a powerful example of how our imaging technology enables customers to provide data to insights quickly and reliably.

With the COVID-19 pandemic impacting millions around the globe, researchers are racing to develop a vaccine or drug treatment. In an effort to better understand the cellular responses to COVID-19, the digital biology company Recursion has publicly released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules on SARS-CoV-2-infected human cells. The images and data were acquired using the ImageXpress Micro Confocal High-Content Imaging System from Molecular Devices, LLC., a leading provider of high-performance bioanalytical measurement solutions.

Named RxRx19, the dataset from Recursion is an important contribution to a growing body of scientific data in the fight against COVID-19. The images and datasets are available and free online, giving researchers open access to both the images and the corresponding deep learning embeddings to analyze or apply to their own experimentation hypothesis.

“We commend Recursion for their leadership around RxRx19, empowering researchers with the statistically relevant data to advance our understanding of COVID-19 cellular responses and drug discovery. It is particularly valuable during this unprecedented time when many labs are operating at reduced capacity or are shutdown altogether due to shelter-in-place requirements,” said Susan Murphy, President of Molecular Devices. “This is a powerful example of how our innovative, high-content imaging technology enables customers to provide data to insights quickly and reliably to help explore treatments for COVID-19.”

Recursion imaged plates using the ImageXpress Micro Confocal system in widefield mode with 20X objectives, acquiring four sites per well with five channels per site. Featuring a unique optical technology that reduces background noise and improves sharpness, Recursion achieved excellent image quality of complex morphological structures—all at the speed of widefield imaging and without sacrificing throughput. Images from the dataset captured with the imaging system can be downloaded here.

Molecular Devices continues to lead the cellular imaging community towards new discoveries utilizing a comprehensive portfolio of powerful yet easy-to-use high-content imaging systems. For more information, visit

About Molecular Devices, LLC.

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

About Recursion

Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, artificial intelligence, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. Recursion’s rich, relatable database of 4.7 petabytes of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. Recursion is proudly headquartered in Salt Lake City. Learn more at, or connect on Twitter and LinkedIn.

Share article on social media or email:

Deadline approaches to file a claim against Purdue on behalf of children born exposed to opioids in womb

The deadline has been extended until July 30, 5 pm ET for presenting a proof of claim to obtain compensation from Purdue Pharma bankruptcy proceedings for a child was born exposed to opioids while in the mother’s womb, resulting in the child exhibiting Neonatal Abstinence Syndrome in the hospital, physical deformities or developmental delays later in childhood, said a representative of Opioid Justice.

Legal and medical representatives of Opioid Justice have been fighting for children born exposed to opioids while fetuses in their mother’s womb to receive funds from the $6 billion made available in the Purdue bankruptcy proceedings, and also encouraging their parents, grandparents, and guardians, to file a proof of claim.

“The COVID-19 national emergency has dominated the news media and other public communications outlets that otherwise could have notified these same parents and guardians of the need to take immediate action in the best interests of their children,” says Brylski, a spokesperson for Opioid Justice and a principal of New Orleans-based Brylski Company.

“We are waving a red flag that families need to contact an attorney today.”

The federal judge overseeing the Purdue bankruptcy proceedings is determined to swiftly reach an agreement over the distribution of the Purdue funds. Opioid Justice offers free advice on how and why to file a claim if someone is parent or guardian to a child with this exposure, and regularly offers free facebook and zoom briefings on the subject.

Brylski says that exposure to opioids in the womb has resulted in birth defects, such as club foot, spina bifida, heart defects, cleft palate, hydrocephalus, esophageal atresia, gastroschisis, anorectal atresia, and diaphragmatic hernia. The most common adverse outcomes upon birth include body shakes, excessive crying or yawning , feeding problems, diarrhea, sleeping problems, fever, or runny noses. As these children grow, many experience behavioral problems, cognitive delays, delayed speech and walking, mental or motor deficits, or attention-deficit disorder (ADD).

Children born exposed or dependent on prescription opioids due to the mother’s use of Oxycotin, Butran, Dilaudid, or other forms of oxycodone, tramadol or related prescription medicines can file a claim by calling (800) 529-8170 or going to

Share article on social media or email:

International Journal of Behavioral Medicine Publishes First Special Issue Focused on Saliva-Based Research

International Journal of Behavioral Medicine

This issue of IJBM illustrates the innovative use of salivary bioscience to answer important behavioral medicine questions.

For researchers in biobehavioral science, Salimetrics has been a reliable partner for over 25 years, providing needed support to navigate research opportunities in the multidisciplinary field of Salivary Bioscience. Utilizing knowledge gained from saliva and oral fluids, Salimetrics continues to facilitate new milestones through an expanding line of high-quality collection devices and assays. Recently, the field has passed several milestones, including saliva-based assays for COVID-19, the release of a foundational reference guide, “Salivary Bioscience Foundations of Interdisciplinary Saliva Research and Applications”, and the first special issue of an international journal devoted to Salivary Bisocience from the IJBM.

The International Journal of Behavioral Medicine (IJBM) is the official scientific journal of the International Society for Behavioral Medicine (ISBM) which aims to present the best theoretically driven, evidence-based work in the field of behavioral medicine from around the globe. The recently published IJBM Special Issue emphasizes saliva-based research utilizing varied research designs (i.e., experimental, longitudinal, dyadic), incorporating a broad array of salivary analytes, and investigating the influence of psychological and social factors on human health. “This issue of IJBM illustrates the innovative use of salivary bioscience to answer important behavioral medicine questions,” says Michael Hoyt, Ph.D., of the Population Health and Disease Prevention and the Chao Family Comprehensive Cancer Center, University of California, Irvine and article contributor. “The interdisciplinary nature of behavioral medicine has expanded and so has its basic scientific and clinical practice missions. It’s distinguished history in understanding behavioral influences on the onset, prevention, and management of disease and on the promotion of well-being and health points the way toward a future of continued innovation and discovery.”

The special issue also features an overview of the use of salivary measures in behavioral medicine with original salivary bioscience studies, reviews of two prominent salivary markers (estradiol and alpha-amylase), and guidance on the physiometrics of salivary data. Several of the studies, supported by Salimetrics tools, were selected as representative of expanding critical mass in behavioral medicine. Specific highlights include:

Hoyt et al., “Salivary Bioscience and the Future of Behavioral Medicine.” This article introduces Salivary Bioscience in Behavioral Medicine and chronicles the overarching aims by translating saliva specimen data to identify mechanisms, decode moderating processes that turn adversity into risk, and verify the impact of clinical intervention.

Segerstrom et al., “Physiometrics in Salivary Bioscience.” This article highlights how studies depend on accurate estimation in statistical models through sample size but also, critically, reliability of the measure itself, and explores which study designs call for stable and generalizable measures.

Riis et al., “Long-Term Associations Between Prenatal Maternal Cortisol and Child Neuroendocrine-Immune Regulation.” This study investigates the relationship of prenatal factors and neuroendocrine-immune dynamics over time. The findings suggest prenatal maternal HPA activity moderates child neuroendocrine-immune functioning.

Eiden et al., “Prenatal Tobacco & Cannabis Exposure: Associations With Cortisol Reactivity in Early School Age Children.” This study lends insight into the potential impact of prenatal tobacco and cannabis exposure and physiological stress responses in later development. Results suggest that prenatal polysubstance exposure is associated with greater risk for lower cortisol response in children.

As Salivary Bioscience continues to expand into new disciplines, Salimetrics is well positioned to provide new, high-quality tools that further advance the field. “We’ve been collaborating with infectious disease researchers for over five years and began our infectious disease initiative about one year ago. This shift in focus made it possible for Salimetrics to have the needed salivary bioscience tools for researchers to monitor inflammation and infectious diseases using oral fluids,” says Supriya Gaitonde, Ph.D., Salimetrics Senior Applications Scientist. “Who is on your research team matters, and Salimetrics has acquired the unique knowledge to get the science right. Our knowledge serves the scientific community, and we give researchers the most effective tools to complete their study.”

Researchers can Contact Salimetrics for more information or review the International Journal for Behavioral Medicine Special Issue on the Springer Website. For more detailed information and examples of the application of salivary bioscience tools in a diverse range of disciplines, readers can refer to; “Salivary Bioscience Foundations of Interdisciplinary Saliva Research and Applications”.

About Salimetrics

Salimetrics’ assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC support CROs, pharmaceuticals, academic researchers and the immunodiagnostic industry around the world with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.

Share article on social media or email:

Ocean Ventures Fiji Launches Cutting-Edge Online Reef Ecology Course

Scuba DIving Undiscovered Biodiversity Healthy Coral Reefs Natewa Bay, Fiji

Scuba diving the undiscovered reefs of Natewa Bay, Fiji

Ocean Ventures are delighted to announce the launch of their brand new online course, South Pacific Coral Reef Ecology, to coincide with World Oceans Day and World Ocean Week. Taking inspiration from a field ecology course they have been teaching for many years, this eLearning course aims to bring coral reef ecology and a love of the marine world to everybody who is unable to travel and experience these amazing ecosystems for themselves during these difficult times.

Bringing Our Vibrant Underwater Cities to Life

This comprehensive program looks at the ecology of coral reefs, starting with their importance as ecosystems, before discussing in detail the amazing biodiversity found on reefs, including the corals themselves, common reef fish, and marine invertebrates. The course then covers the intrinsically-linked ecosystems, mangroves and seagrasses, before concluding with a detailed look at the threats faced by coral reefs and the actions being taken to preserve these wonders of nature.

Although the majority of the course content is applicable to all coral reefs globally, each section also includes significant local context with many examples from reefs in the South Pacific. Stunning photos and underwater videos illustrate the course, most shot in Natewa Bay by the Ocean Ventures team themselves. Although it is the largest bay in the South Pacific, Natewa Bay remains a little-known gem home to pristine reefs and incredible biodiversity.

Gaining Knowledge and Earning New Qualifications

This eLearning course can be taken either as a standalone program at US $50, or with certification in Ocean Ventures’ exclusive PADI distinctive specialty, PADI South Pacific Coral Reef Ecology at US $95. Ocean Ventures will deduct the basic cost of US $50 from selected diving courses and dive packages for anybody diving with Ocean Ventures Fiji in the future.

The course is hosted on the established teaching platform which uses a secure 128-bit SSL encrypted payment system.

Inclusive Access to Coral Reef Education

Who might be interested in this online reef ecology course?

  • Anybody with an interest in coral reefs globally and/or marine conservation
  • Anybody with a general interest in our oceans and the environment
  • Anybody with a specific interest in the coral reefs of the South Pacific
  • Anybody who planned an ocean-based trip but is currently unable to travel due to restrictions
  • Scuba divers and snorkelers
  • Divers looking for an additional certification (this PADI specialty can credit towards PADI Master Scuba Diver)
  • Students interested in the fields of marine science or marine biology
  • Underwater photographers looking to improve their knowledge of marine creatures and basic ID skills

Anyone who would like to join the course can visit

. An introductory video giving an outline of the course is available as a free preview on that page, and on the Ocean Ventures Fiji YouTube channel.

Any other questions can be directed to Matthew and Sara at, or via their website,


About Ocean Ventures

Ocean Ventures Fiji is the first and only scuba diving centre in the beautiful Natewa Bay, offering scuba diving, snorkeling and conservation education. Directors Sara Carlson and Matthew Norman bring a wealth of experience, having worked as site managers, reef ecology lecturers or PADI scuba instructors in Indonesia, Greece, Mexico, Dominica and Honduras. Sara, from the United States, and Matthew, from the United Kingdom, founded Ocean Ventures Fiji in 2017, based in the pristine and unexplored natural wonder that is Natewa Bay near Savusavu. Ocean Ventures focuses on providing the very best experience possible, with small group sizes, excellent customer service and personal attention. All operations are planned with safety in mind, accordingto the highest standards of safe diving practice with impeccably-maintained equipment from the most recognized brands in the diving industry.

Press Contacts:

Matthew Norman & Sara Carlson

+679 9295803 or 9531800

Share article on social media or email: